Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

10 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from human cord blood CD161++/CD161+/CD161- CD8+ T cell subsets

ABSTRACT: We used microarray to compare gene expression between CD161++/CD161+/CD161-CD8+ T cells from human cord blood. Lymphocytes from freshly obtained human cord blood samples were isolated by Ficoll density centrifugation. CD8+ T cells were purified by negative selection using magnetic beads and subsequently labelled with fluorescent antibodies prior to sorting using MoFlo MLS cell sorter (Dako).

ORGANISM(S): Homo sapiens

SUBMITTER: Natasha Sahgal

PROVIDER: E-GEOD-33424 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells.

Walker Lucy J LJ Kang Yu-Hoi YH Smith Matthew O MO Tharmalingham Hannah H Ramamurthy Narayan N Fleming Vicki M VM Sahgal Natasha N Leslie Alistair A Oo Ye Y Geremia Alessandra A Scriba Thomas J TJ Hanekom Willem A WA Lauer Georg M GM Lantz Olivier O Adams David H DH Powrie Fiona F Barnes Eleanor E Klenerman Paul P

Blood 20111115 2

Human mucosal associated invariant T (MAIT) CD8(+) and Tc17 cells are important tissue-homing cell populations, characterized by high expression of CD161 ((++)) and type-17 differentiation, but their origins and relationships remain poorly defined. By transcriptional and functional analyses, we demonstrate that a pool of polyclonal, precommitted type-17 CD161(++)CD8αβ(+) T cells exist in cord blood, from which a prominent MAIT cell (TCR Vα7.2(+)) population emerges post-natally. During this expa ...[more]

PMID: 22086415

Similar Datasets

Expression data from healthy human CD161++CD8aa and CD161++CD8ab T cells

Project description:We used microarrays to compare gene expression between healthy human CD161++CD8aa and CD161++CD8ab T cells. We sorted freshly obtained peripheral blood mononucleocytes from healthy controls by first using magnetic beads to negatively select for CD8a+ T cells, fluorescently labelling isolated cells with antibodies and subsequent sorting using MoFlow MLS cell sorter (DAKO). Sorted samples were snap frozen. RNA was later extracted from the sorted populations prior to hybridization to Affymetrix arrays.

2012-01-25 | E-GEOD-33374 | biostudies-arrayexpress

Human MAIT and CD8++ cell development

Project description:This SuperSeries is composed of the following subset Series: GSE33374: Expression data from healthy human CD161++CD8aa and CD161++CD8ab T cells GSE33424: Expression data from human cord blood CD161++/CD161+/CD161- CD8+ T cell subsets Refer to individual Series

2012-01-25 | E-GEOD-33425 | biostudies-arrayexpress

Expression data from human cord blood CD161++/CD161+/CD161- CD8+ T cell subsets

Project description:We used microarray to compare gene expression between CD161++/CD161+/CD161-CD8+ T cells from human cord blood.

2012-01-25 | GSE33424 | GEO

CD161 defines a transcriptional and functional phenotype shared across distinct human T cell lineages (CD 8)

Project description:T lymphocytes are conventionally divided into subsets based upon expression of co-receptors, cytokines and surface molecules. By mRNA microarray analysis, T lymphocytes that express the C-type lectin CD161 were identified to share a transcriptional profile, which led to the identification of an innate function across these previously defined subsets, including CD8, CD4 and TCRgd T cells. Gene expression of sort purified, resting CD161++, CD161+ and CD161- CD8+ T cells from peripheral blood was measured in 4 healthy donors.

2014-10-07 | E-GEOD-62096 | biostudies-arrayexpress

CD161 defines a transcriptional and functional phenotype shared across distinct human T cell lineages (TCRgd)

Project description:T lymphocytes are conventionally divided into subsets based upon expression of co-receptors, cytokines and surface molecules. By mRNA microarray analysis, T lymphocytes that express the C-type lectin CD161 were identified to share a transcriptional profile, which led to the identification of an innate function across these previously defined subsets, including CD8, CD4 and TCRgd T cells. Gene expression of sort purified, resting CD161+ and CD161- TCRgd T cells from peripheral blood was measured in 4 healthy donors.

2014-10-07 | E-GEOD-62097 | biostudies-arrayexpress

CD161 defines a transcriptional and functional phenotype shared across distinct human T cell lineages (CD4)

Project description:T lymphocytes are conventionally divided into subsets based upon expression of co-receptors, cytokines and surface molecules. By mRNA microarray analysis, T lymphocytes that express the C-type lectin CD161 were identified to share a transcriptional profile, which led to the identification of an innate function across these previously defined subsets, including CD8, CD4 and TCRgd T cells. Gene expression of magnetically enriched, resting CD161+ and CD161- CD4+ T cells from peripheral blood was measured in 3 healthy donors.

2014-10-07 | E-GEOD-62095 | biostudies-arrayexpress

Expression data from healthy human CD161++CD8aa and CD161++CD8ab T cells

Project description:We used microarrays to compare gene expression between healthy human CD161++CD8aa and CD161++CD8ab T cells.

2012-01-25 | GSE33374 | GEO

Targeting of the CD161 Inhibitory Receptor Enhances T cell-mediated Immunity Against Hematological Malignancies

Project description:The CD161 inhibitory receptor is highly upregulated by tumor-infiltrating T cells in a number of human solid tumor types, and its ligand CLEC2D is expressed by both tumor cells and infiltrating myeloid cells. Here we assessed the role of the CD161 receptor in hematological malignancies. Systematic analysis of CLEC2D expression using the Cancer Cell Line Encyclopedia (CCLE) revealed that CLEC2D mRNA was most abundant in hematological malignancies, including B cell and T cell lymphomas as well as lymphocytic and myelogenous leukemias. CLEC2D protein was detected by flow cytometry on a panel of cell lines representing a diverse set of hematological malignancies. We therefore used yeast display to generate a panel of high-affinity, fully human CD161 monoclonal antibodies (mAbs) that blocked CLEC2D binding. These mAbs were specific for CD161 and had a similar affinity for human and non-human primate CD161, a property relevant for clinical translation. A high-affinity CD161 mAb enhanced key aspects of T cell function, including cytotoxicity, cytokine production and proliferation, against cell lines originating from patients with AML, DLBCL and Burkitt lymphoma. In humanized mouse models, this CD161 mAb enhanced T cell-mediated immunity resulting in a significant survival benefit. ScRNA-seq data demonstrated that CD161 mAb treatment enhanced expression of cytotoxicity genes by CD4 T cells as well as a tissue-resident memory program by CD4 and CD8 T cells that is associated with favorable survival outcomes in multiple human cancer types. These fully human monoclonal antibodies thus represent potential immunotherapy agents for hematological malignancies.

2024-01-02 | GSE220200 | GEO

Homo sapiens

Project description:Expression data from human cord blood CD161++/CD161+/CD161- CD8+ T cell subsets

| PRJNA154253 | ENA

Gene expression profile of TCR Vdelta1 positive gammadelta T cells expressed CD161

Project description:To elucidate the difference between CD161-negative TCR Vdelta1 and CD161-positive TCR Vdelta1 cells, we performed GeneChip analysis of these two types of cells in peripheral blood mononuclear cells from healthy donors. Such analysis identified 192 genes that were expressed at two-fold or higher levels on CD161-positive TCR Vdelta1 cells than on CD161-negative TCR Vdelta1 cells. Expression of three genes (CCL3, CCL4 and CD161) from this signature was quantified in the same RNA samples by real-time PCR. CD161-negative and CD161-positive TCR Vdelta1cells of three healthy volunteers were isolated from freshly peripheral blood mononuclear cells.

2014-01-09 | E-GEOD-43402 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data